What is MicuRx?
MicuRx Pharmaceuticals, Inc. is a global biopharmaceutical entity established in 2007, dedicated to the design, discovery, and development of novel medicines for infectious diseases and critical unmet medical needs. The company places a particular emphasis on combating drug-resistant bacterial infections, aiming to pioneer the next generation of safe and effective antibiotics. With a strategic presence in Shanghai, California, and Beijing, MicuRx is committed to advancing its robust research and development pipeline through active engagement in clinical trials and research studies, addressing significant clinical challenges.
How much funding has MicuRx raised?
MicuRx has raised a total of $219.9M across 6 funding rounds:
Series A
$10M
Series B
$25M
Series C
$55M
Series D
$15.1M
Other Financing Round
$7.8M
Series E
$107M
Series A (2007): $10M with participation from Morningside Group
Series B (2013): $25M led by Devon Park Bioventures, BVCF Management, and Morningside Group
Series C (2016): $55M supported by 3E Bioventures Capital, Delin Capital, and 3E Bioventures Capital
Series D (2017): $15.1M featuring Delin Capital, BVCF Management, and HG Capital
Other Financing Round (2020): $7.8M backed by Carb-X
Series E (2020): $107M with participation from Detong Capital, Zhongtai Ventures, Founder H Fund, China Merchants Securities Co. Ltd, Korea Investment Partners, and Yingke PE
Key Investors in MicuRx
Founder H Fund
Founder H Fund, also known as 方正金融, is an investment firm specializing in private equity with a focus on healthcare and technology. They manage substantial funds targeting medical services, devices, and precision medicine, indicating a strategic interest in innovative healthcare solutions.
Korea Investment Partners
While the provided domain information is for Korea Water Technology, Korea Investment Partners is a significant venture capital firm known for investing in various technology and growth-stage companies, suggesting a broad investment mandate.
Delin Capital
Delin Capital, through its property arm, specializes in logistics real estate, but its participation in MicuRx's funding suggests a diversified investment strategy or a specific interest in the life sciences sector's growth potential.
What's next for MicuRx?
The substantial enterprise-level funding, including the recent major strategic investment, indicates MicuRx is likely in a scaling or late-stage development phase. This capital infusion is expected to accelerate the advancement of its antibiotic pipeline through clinical trials and potentially towards commercialization. The company's focus on drug-resistant infections positions it to address a critical global health crisis, suggesting a strategic expansion of its research capabilities and market reach.
See full MicuRx company page
